Evidence map›Paper›PMID 31826890›Full record

ArticleBMJ open2019

Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis.

Ada Miltz, Fiona Lampe, Sheena McCormack, David Dunn, Ellen White, Alison Rodger, Andrew Phillips, Lorraine Sherr, Ann K Sullivan, Iain Reeves and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02065986 (Pre-exposure Option for Reducing HIV in the UK), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02065986 phase4completednot on this map

Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD)

TypeinterventionalSponsorMRC [ycm]Ran2012 to 2016Enrolled544ConditionsHIVArmsTruvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ada MiltzInstitute for Global Health, University College London, London, UK Ada.Miltz.11@ucl.ac.uk.ORCID 0000-0003-2771-7880
Fiona LampeInstitute for Global Health, University College London, London, UK.
Sheena McCormackMRC CTU, University College London, London, UK.
David DunnMRC CTU, University College London, London, UK.
Ellen WhiteMRC CTU, University College London, London, UK.
Alison RodgerInstitute for Global Health, University College London, London, UK.
Andrew PhillipsInstitute for Global Health, University College London, London, UK.
Lorraine SherrInstitute for Global Health, University College London, London, UK.
Ann K SullivanChelsea and Westminster Healthcare NHS Trust, London, UK.
Iain ReevesHomerton University Hospital NHS Trust, London, UK.
Amanda ClarkeBrighton & Sussex University Hospital NHS Trust, Brighton & Sussex Medical School, Brighton, UK.
Mitzy GafosDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
University College London · GBBrighton and Sussex Medical School · GBHomerton University Hospital · GBLondon School of Hygiene & Tropical Medicine · GB

Funding

Medical Research Council MC_UU_12023/23
6 · The paper itself

Abstract

objectivesThe aim of this analysis is to: (i) assess the prevalence of clinically significant depressive symptoms at baseline and follow-up for participants in the PROUD trial of HIV pre-exposure prophylaxis (PrEP), examining changes in prevalence over time and (ii) investigate the association of socioeconomic and psychosocial factors with depression.

methodsPROUD was an open label randomised trial evaluating the benefit of PrEP for 544 HIV-negative gay, bisexual and other men who have sex with men (GBMSM) in England. Enrolment was between 2012 and 2014, with at least 2 years follow-up. Prevalence of depression (score ≥10 on Patient Health Questionnaire-9) was assessed and compared across time-points (using McNemar's χ

resultsDepression increased significantly from baseline (9.1%; 49/540) to the 12 month (14.4%; 59/410) and 24 month (14.4%; 48/333) follow-ups, possibly explained by underreporting at baseline. The prevalence of depression did not differ by study trial arm, at any time-point. In the baseline analysis, younger age, unemployment and crystal methamphetamine use, was associated with depression. In combined analysis of 12 and 24 month data, measures of intimate partner violence (IPV) (lifetime IPV victimisation aPR 2.57 (95% CI: 1.71 to 3.86)), internalised homophobia (aPR 1.91 (95% CI: 1.29 to 2.83)) and concealment of sexual identity (aPR 1.75 (95% CI: 1.16 to 2.65)), were strongly associated with depression.

conclusionsThere is a high concomitant burden of psychosocial factors with depression among GBMSM. TRIAL REGISTRATION NUMBER: ISRCTN (ISRCTN94465371) and ClinicalTrials.gov (NCT02065986).

Indexed as

Sexual and Gender MinoritiesAdultBisexualityCorrelation of DataCross-Sectional StudiesDepressionEnglandHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedPre-Exposure ProphylaxisPrevalenceRandomized Controlled Trials as TopicSocioeconomic Factorsepidemiologygenitourinary medicinemental healthpublic health

Identifiers

PMID31826890
PMCPMC6924847
OpenAlexW2994689517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.